174 related articles for article (PubMed ID: 27343732)
1. HIV-1 Vpr increases Env expression by preventing Env from endoplasmic reticulum-associated protein degradation (ERAD).
Zhang X; Zhou T; Frabutt DA; Zheng YH
Virology; 2016 Sep; 496():194-202. PubMed ID: 27343732
[TBL] [Abstract][Full Text] [Related]
2. The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway.
Zhou T; Dang Y; Zheng YH
J Virol; 2014 Mar; 88(6):3474-84. PubMed ID: 24403586
[TBL] [Abstract][Full Text] [Related]
3. Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression.
Wang Q; Su L
mBio; 2019 Aug; 10(4):. PubMed ID: 31431548
[TBL] [Abstract][Full Text] [Related]
4. ERManI (Endoplasmic Reticulum Class I α-Mannosidase) Is Required for HIV-1 Envelope Glycoprotein Degradation via Endoplasmic Reticulum-associated Protein Degradation Pathway.
Zhou T; Frabutt DA; Moremen KW; Zheng YH
J Biol Chem; 2015 Sep; 290(36):22184-92. PubMed ID: 26205822
[TBL] [Abstract][Full Text] [Related]
5. Evidence for Vpr-dependent HIV-1 replication in human CD4+ CEM.NKR T-cells.
Zhou T; Dang Y; Baker JJ; Zhou J; Zheng YH
Retrovirology; 2012 Nov; 9():93. PubMed ID: 23134572
[TBL] [Abstract][Full Text] [Related]
6. Vpr overcomes macrophage-specific restriction of HIV-1 Env expression and virion production.
Mashiba M; Collins DR; Terry VH; Collins KL
Cell Host Microbe; 2014 Dec; 16(6):722-35. PubMed ID: 25464830
[TBL] [Abstract][Full Text] [Related]
7. Mannose receptor is an HIV restriction factor counteracted by Vpr in macrophages.
Lubow J; Virgilio MC; Merlino M; Collins DR; Mashiba M; Peterson BG; Lukic Z; Painter MM; Gomez-Rivera F; Terry V; Zimmerman G; Collins KL
Elife; 2020 Mar; 9():. PubMed ID: 32119644
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Vpr Induces Degradation of Gelsolin, a Myeloid Cell-Specific Host Factor That Reduces Viral Infectivity by Inhibiting the Expression and Packaging of the HIV-1 Env Glycoprotein.
Fabryova H; Kao S; Sukegawa S; Miyagi E; Taylor L; Ferhadian D; Saito H; Schaal H; Hillebrand F; Strebel K
mBio; 2023 Feb; 14(1):e0297322. PubMed ID: 36602307
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vpr increases HCV replication through VprBP in cell culture.
Yan Y; Huang F; Yuan T; Sun B; Yang R
Virus Res; 2016 Sep; 223():153-60. PubMed ID: 27460548
[TBL] [Abstract][Full Text] [Related]
10. Protein Arginine
Murakami H; Suzuki T; Tsuchiya K; Gatanaga H; Taura M; Kudo E; Okada S; Takei M; Kuroda K; Yamamoto T; Hagiwara K; Dohmae N; Aida Y
Viruses; 2020 Mar; 12(3):. PubMed ID: 32210193
[TBL] [Abstract][Full Text] [Related]
11. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication.
Kuwata T; Igarashi T; Ido E; Jin M; Mizuno A; Chen J; Hayami M
J Gen Virol; 1995 Sep; 76 ( Pt 9)():2181-91. PubMed ID: 7561755
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vpr reactivates latent HIV-1 provirus by inducing depletion of class I HDACs on chromatin.
Romani B; Kamali Jamil R; Hamidi-Fard M; Rahimi P; Momen SB; Aghasadeghi MR; Allahbakhshi E
Sci Rep; 2016 Aug; 6():31924. PubMed ID: 27550312
[TBL] [Abstract][Full Text] [Related]
13. Reduction of HIV-1 infectivity through endoplasmic reticulum-associated degradation-mediated Env depletion.
Casini A; Olivieri M; Vecchi L; Burrone OR; Cereseto A
J Virol; 2015 Mar; 89(5):2966-71. PubMed ID: 25540359
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Vpr mediates the depletion of the cellular repressor CTIP2 to counteract viral gene silencing.
Forouzanfar F; Ali S; Wallet C; De Rovere M; Ducloy C; El Mekdad H; El Maassarani M; Aït-Ammar A; Van Assche J; Boutant E; Daouad F; Margottin-Goguet F; Moog C; Van Lint C; Schwartz C; Rohr O
Sci Rep; 2019 Sep; 9(1):13154. PubMed ID: 31511615
[TBL] [Abstract][Full Text] [Related]
15. Illuminating the Role of Vpr in HIV Infection of Myeloid Cells.
Nodder SB; Gummuluru S
Front Immunol; 2019; 10():1606. PubMed ID: 31396206
[TBL] [Abstract][Full Text] [Related]
16. The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction.
Wu Y; Zhou X; Barnes CO; DeLucia M; Cohen AE; Gronenborn AM; Ahn J; Calero G
Nat Struct Mol Biol; 2016 Oct; 23(10):933-940. PubMed ID: 27571178
[TBL] [Abstract][Full Text] [Related]
17. GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.
Jejcic A; Höglund S; Vahlne A
Retrovirology; 2010 Mar; 7():20. PubMed ID: 20230608
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
19. Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages.
Zhao L; Wang S; Xu M; He Y; Zhang X; Xiong Y; Sun H; Ding H; Geng W; Shang H; Liang G
Nat Commun; 2021 Jun; 12(1):3691. PubMed ID: 34140527
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vpr hijacks EDD-DYRK2-DDB1
Hossain D; Ferreira Barbosa JA; Cohen ÉA; Tsang WY
J Biol Chem; 2018 Jun; 293(24):9448-9460. PubMed ID: 29724823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
